EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance

Lidi Nan, Liandi Chen, Weifeng Huang, Shaogang Peng, Chao Wang, Huayuan Liao, Yifei Wang, Ziyue Cui, Yanqing Lv, Xiaomu Wang, Yi Luo, Andy Tsun und 2 weitere

Journal for ImmunoTherapy of Cancer · 2025-12 · 13 (12) · e013283

DOI: 10.1136/jitc-2025-013283 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 11.12.2025. Verfasst von Lidi Nan und 13 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Science and Technology, China Pharmaceutical University, Nanjing, China. Hauptthemen laut MEDLINE: CD47 Antigen, Antibodies, Bispecific, CD24 Antigen, Immunity, Innate. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Tumor-associated macrophages (TAMs) abundantly infiltrate tumors and possess potent antitumor capabilities. “Don‘t eat me” signals like CD47 allow tumors to evade macrophages and proliferate unchecked. CD47 is upregulated in many tumors and interacts with the SIRPα expressed on macrophages to restrict effector function. Similarly, CD24 interacts with the Siglec-10 on TAMs to inhibit engulfment. Despite their potential, there is still a lack of effective therapeutics targeting macrophages. Recent clinical trials targeting CD47 have demonstrated limited efficacy and significant side effects in solid tumors, primarily due to the expression of CD47 on healthy cells such as red blood cells (RBCs). We therefore developed novel anti-CD47 variable domain of heavy chain of heavy-chain antibodies (vHHs) with strong ligand-blocking activity while demonstrating minimal binding to RBCs and incorporated these vHHs to generate an anti-CD47/CD24 bispecific antibody that preserves Fc-effector function and achieves improved tumor targeting while maintaining the blockade of antiphagocytic signals elicited by both CD47 and CD24.

Methods

Yeast display was employed to generate vHHs targeting CD47 and fully human monoclonal antibodies against CD24, respectively. The antigen binding epitopes of the vHHs to CD47 were predicted using AlphaFold3. Bispecific antibodies were designed, constructed, and characterized in vitro. Antitumor efficacy was evaluated in a human immune cell reconstitution mouse model, while safety was evaluated using a humanized syngeneic mouse model. Furthermore, the underlying mechanisms and alterations in tumor microenvironment were explored ex vivo.

Results

VHHs targeting CD47 and a fully human antibody against CD24 were identified, all exhibiting potent ligand-blocking activity. The bispecific antibody BiAb-103C, engineered on a human IgG1 scaffold, had strong binding to CD47 + CD24 + tumor cells and could effectively inhibit the CD47-SIRPα interaction. Fc-effector activity was observed towards CD24 (but not CD47) single-positive cells to promote phagocytosis and antibody-dependent cellular cytotoxicity of CD47 + CD24 + tumor cells. In mice, antibody candidates demonstrated notable antitumor activity alongside favorable safety observations.

Conclusions

Our study presents the discovery of an anti-CD47/CD24 bispecific antibody that offers a promising therapeutic strategy to address the challenges associated with both the efficacy and safety of CD47-targeting agents, offers insight into macrophage-driven cancer immunotherapy, and could potentially provide a therapeutic option for patients non-responsive to immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD47 AntigenAntibodies, BispecificCD24 AntigenImmunity, InnateNeoplasmsAnimalsHumansMiceFemaleCell Line, Tumor

Stichwörter der Autor:innen

AntibodyImmune Checkpoint InhibitorImmunotherapyMacrophage

Substanzen

CD47 AntigenAntibodies, BispecificCD24 AntigenCD47 protein, human

Autor:innen und Institutionen

  • School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
  • Biotheus Inc, Zhuhai, China.
  • Biotheus (Suzhou) Co. Ltd, Suzhou, China.
  • Clinical Pharmacy lnnovation lnstitute, Shanghai Jiao Tong University of Medicine, Shanghai, China.
  • Biotheus Inc, Zhuhai, China zhangjuan@cpu.edu.cn miao.xn@biotheus.com tsun.a@biotheus.com.
  • School of Life Science and Technology, China Pharmaceutical University, Nanjing, China zhangjuan@cpu.edu.cn miao.xn@biotheus.com tsun.a@biotheus.com.

Zitieren

APA

Nan, L., Chen, L., Huang, W., Peng, S., Wang, C., Liao, H., Wang, Y., Cui, Z., Lv, Y., Wang, X., Luo, Y., Tsun, A., Miao, X., & Zhang, J. (2025). Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance. Journal for ImmunoTherapy of Cancer, 13(12), e013283. https://doi.org/10.1136/jitc-2025-013283

Vancouver

Nan L, Chen L, Huang W, Peng S, Wang C, Liao H, et al. Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance. Journal for ImmunoTherapy of Cancer. 2025;13(12):e013283. doi:10.1136/jitc-2025-013283

BibTeX
@article{Nan2025,
  author = {Nan, Lidi and Chen, Liandi and Huang, Weifeng and Peng, Shaogang and Wang, Chao and Liao, Huayuan and Wang, Yifei and Cui, Ziyue and Lv, Yanqing and Wang, Xiaomu and Luo, Yi and Tsun, Andy and Miao, Xiaoniu and Zhang, Juan},
  title = {Harnessing the innate immune system: a novel bispecific antibody targeting CD47 and CD24 for selective tumor clearance},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  volume = {13},
  number = {12},
  pages = {e013283},
  doi = {10.1136/jitc-2025-013283}
}
Kostenlos starten →